A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 637-644

  Brams, Matthew ^a   Turnbow, John ^b   Pestreich, Linda ^c   Giblin, John ^d   Childress, Ann ^e   McCague, Kevin ^f   Muniz, Rafael ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Westex Clinical Investigations   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Clinical Study Centers LLC   (United States)

^e Center for Psychiatry and Behavioral Medicine Inc   (United States)

^f Clinical Biostatistics   (United States)

Author keywords

ADHD; children; dexmethylphenidate; late day control

Indexed keywords

DEXMETHYLPHENIDATE; METHYLPHENIDATE; PLACEBO;

ABDOMINAL PAIN; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; ORAL BLISTER; PERITONSILLAR ABSCESS; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SUSTAINED RELEASE FORMULATION; TACHYCARDIA; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865860756     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182677825     Document Type: Article

References (40)

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366:237-248.
2. Froehlich TE, Lanphear BP, Epstein JN, et al. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med. 2007;161:857-864.
3. Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry. 1996;53:437-446.
4. Liu YH, Stein MT. Attention-deficit/hyperactivity disorder: evidence-based diagnosis and management for primary care clinicians. Minerva Pediatr. 2004;56:567-583.
5. Edbom T, Lichtenstein P, Granlund M, et al. Long-term relationships between symptoms of attention deficit hyperactivity disorder and self-esteem in a prospective longitudinal study of twins. Acta Paediatr. 2006;95:650-657.
6. Wilens TE, Dodson W. A clinical perspective of attention-deficit/ hyperactivity disorder into adulthood. JClinPsychiatry. 2004;65:1301-1313.
7. Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. Eur Child Adolesc Psychiatry. 2010;19:325-340.
8. Coghill D, Soutullo C, d'Aubuisson C, et al. Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adolesc Psychiatry Ment Health. 2008;2:31.
9. Srinivas NR, Hubbard JW, Quinn D, et al. Enantioselective pharmacokinetics and pharmacodynamics of DL-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther. 1992;52:561-568.
10. Markowitz JS, DeVane CL, Pestreich LK, et al. A comprehensive in vitro screening of D-, L-, and DL-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006;16:687-698.
11. Quinn D, Wigal S, Swanson J, et al. Comparative pharmacodynamics and plasma concentrations of D-threo-methylphenidate hydrochloride after single doses of D-threo-methylphenidate hydrochloride and D,L-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004;43:1422-1429.
12. Novartis Pharmaceuticals Corporation. Focalin XR prescribing information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/focalinXR.pdf. Accessed January 2011.
13. Brams M, Muniz R, Childress A, et al. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect. CNS Drugs. 2008;22:693-704.
14. Silva R, Muniz R, McCague K, et al. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting. Psychopharmacol Bull. 2008;41:19-33.
15. Silva RR, Muniz R, Pestreich L, et al. Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2008;47:199-208.
16. Muniz R, Brams M, Mao A, et al. Efficacy and safety of extended-release dexmethylphenidate compared with D,L-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol. 2008;18: 248-256.
17. Silva RR, Muniz R, Pestreich L, et al. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2006;16:239-251.
18. Wigal S, Swanson JM, Feifel D, et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and D,L-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004;43:1406-1414.
19. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108:1033-1044.
20. Swanson J, Kinsbourne M, Roberts W, et al. Time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics. 1978;61:21-29.
21. Swanson JM, Wigal SB, Udrea D, et al. Evaluation of individual subjects in the analog classroom setting: I. Examples of graphical and statistical procedures for within-subject ranking of responses to different delivery patterns of methylphenidate. Psychopharmacol Bull. 1998;34:825-832.
22. Swanson J. School Based Assessments and Interventions for ADHD Students. Irvine, CA: K. C. Publishing; 1992.
23. Wigal SB, Gupta S, Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull. 1998;34:47-53.
24. Swanson J, Wigal S, Greenhill L, et al. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull. 1998;34:55-60.
25. Swanson JM, Wigal S, Greenhill LL, et al. Analog classroom assessment of Adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry. 1998;37:519-526.
26. Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics. 2004;113: e206Ye216.
27. Buitelaar JK, van der Gaag RJ, Swaab-Barneveld H, et al. Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:1025-1032.
28. Hechtman L. Predictors of long-term outcome in children with attention-deficit/hyperactivity disorder. Pediatr Clin North Am. 1999;46:1039-1052.
29. van der Oord S, Prins PJ, Oosterlaan J, et al. Treatment of attention deficit hyperactivity disorder in children. Predictors of treatment outcome. Eur Child Adolesc Psychiatry. 2008;17:73-81.
30. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000; 105:1158-1170.
31. Robison LM, Skaer TL, Sclar DA, et al. Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants. CNS Drugs. 2002;16:129-137.
32. Castle L, Aubert RE, Verbrugge RR, et al. Trends in medication treatment for ADHD. J Atten Disord. 2007;10:335-342.
33. Ramtekkar UP, Reiersen AM, Todorov AA, et al. Sex and age differences in attention-deficit/hyperactivity disorder symptoms and diagnoses: implications for DSM-V and ICD-11. J Am Acad Child Adolesc Psychiatry. 2010;49:217-228.
34. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402-409.
35. Simon V, Czobor P, Balint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194:204-211.
36. Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110:258-266.
37. Steele M, Weiss M, Swanson J, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 2006;13:e50Ye62.
38. Wigal SB, Kollins SH, Childress AC, et al. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3:17.
39. Dickson RA, Maki E, Gibbins C, et al. Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/ hyperactivity disorder: analysis of Canadian open-label studies. Child Adolesc Psychiatry Ment Health. 2011;5:14.
40. Biederman J, Mick E, Faraone SV, et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry. 2002;159:36-42.